ALEMBICLTDNSEAlembic Limited· PharmaceuticalsHighNeutral
Announced Tue, 19 May · 17:55 IST

Alembic Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Emphasis Of MatterContingent Liabilities IncreasedRevenue Growth 20pctResults View source PDF

ALEMBICLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹89.70
prior close
₹87.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.4+0.5+0.7-2.5-2.5-1.9-1.5-2.9-3.2-4.3+2.1+0.9
Up moveDown movePending
AI summary

Alembic Limited reported consolidated revenue of Rs 23,999 lakhs for FY26, up 8.2% from Rs 22,189 lakhs in FY25. Net profit after tax including share of associate grew marginally to Rs 31,738 lakhs from Rs 31,068 lakhs. However, standalone net profit declined 12.3% to Rs 12,454 lakhs from Rs 14,195 lakhs. The company operates in two segments - Active Pharmaceutical Ingredients (API) and Real Estate, with Real Estate contributing ~81% of revenue. The Board recommended dividend of Rs 2.40 per share (120%) at same level as previous year. Auditors issued unmodified opinion on both consolidated and standalone results. An emphasis of matter was raised regarding a disputed electricity duty matter where Rs 2,052.13 lakhs provision has been made and Rs 3,500 lakhs deposited with Supreme Court.

Likely market impact

Revenue grew modestly but standalone profitability declined. The electricity duty dispute remains a contingent liability requiring shareholder attention. Positive operating cash flows of Rs 12,007 lakhs indicate strong cash generation. The unchanged dividend reflects management confidence despite profit pressure.